Soucek J, Marinov I, Benes J, Hilgert I, Matousek J, Raines R T
Department of Cell Physiology, Czech Academy of Sciences, Prague, Czech Republic.
Immunobiology. 1996 Aug;195(3):271-85. doi: 10.1016/S0171-2985(96)80045-3.
Two preparations of dimeric BS RNase-native and recombinant proteins caused identical immunosuppressive effects on MLC-stimulated human lymphocytes. The monomers of RNase A and BS RNase were ten times less active. The inhibitory effect on MLC-stimmulation was followed by 90% inhibition of cell-mediated lympholysis (CML) caused by BS RNase (10 micrograms/ml). This effect indicated that BS RNase suppressed the recognition phase of the cytotoxic reaction, resulting in inhibition of generation of cytotoxic effector cells. BS RNase exerted a similar effect on generation of cytotoxic LAK cells. Cytotoxic activity of LAK cells or CTLs against K562 target cells was abrogated only when BS RNase was added at the beginning of the sensitizing phase, but the cytotoxicity of effector cells in the destruction phase was not influenced. The effect of RNase A on the generation of cytotoxic cells was much less pronounced. To get more information about the site of action, the effect of BS RNase on early lymphocyte stimulation by PHA was investigated by using fluorescein cell probes. BS RNase (100 micrograms/ml) prevented a shift in fluorescein emission occurring within one hour of activation using fluorescein diacetate as a marker for changes in the cytoplasmic matrix. On the contrary, it did not block the shift in fluorescence emission when tested with diphenylhexatrien as a marker for changes in membrane fluidity. Furthermore the effect of BS RNase on expression of membrane antigens expressed on activated human lymphocytes was estimated. BS RNase significantly inhibited the expression of CD25, CD38 and CD71 antigens on PHA-, Con A- and MLC-stimulated human T and B lymphocytes. No substantial change in expression of these antigens was observed on IL-2-stimulated cells, but DNA synthesis was totally abrogated. These results indicate that the mode of action of BS RNase on activated T and B lymphocytes is based mainly on the suppressed expression of receptors for interleukin-2-alpha-chain and transferrin.
两种二聚体BS核糖核酸酶制剂——天然蛋白和重组蛋白,对混合淋巴细胞培养(MLC)刺激的人淋巴细胞产生相同的免疫抑制作用。核糖核酸酶A和BS核糖核酸酶的单体活性低10倍。对MLC刺激的抑制作用之后,BS核糖核酸酶(10微克/毫升)对细胞介导的淋巴细胞溶解(CML)产生90%的抑制作用。这种作用表明BS核糖核酸酶抑制了细胞毒性反应的识别阶段,导致细胞毒性效应细胞的生成受到抑制。BS核糖核酸酶对细胞毒性LAK细胞的生成也有类似作用。只有在致敏阶段开始时加入BS核糖核酸酶,LAK细胞或细胞毒性T淋巴细胞(CTL)对K562靶细胞的细胞毒性才会消除,但效应细胞在破坏阶段的细胞毒性不受影响。核糖核酸酶A对细胞毒性细胞生成的作用则不那么明显。为了获取更多关于作用位点的信息,使用荧光素细胞探针研究了BS核糖核酸酶对PHA早期淋巴细胞刺激的影响。BS核糖核酸酶(100微克/毫升)阻止了在使用二乙酸荧光素作为细胞质基质变化标记物激活1小时内发生的荧光素发射变化。相反,当用二苯基己三烯作为膜流动性变化标记物进行测试时,它并未阻止荧光发射变化。此外,还评估了BS核糖核酸酶对活化的人淋巴细胞上表达的膜抗原的影响。BS核糖核酸酶显著抑制PHA、刀豆蛋白A和MLC刺激的人T和B淋巴细胞上CD25、CD38和CD71抗原的表达。在IL-2刺激的细胞上未观察到这些抗原表达的实质性变化,但DNA合成完全被消除。这些结果表明,BS核糖核酸酶对活化的T和B淋巴细胞的作用方式主要基于对白细胞介素-2α链和转铁蛋白受体表达的抑制。